Cardiology

Episodes 49-64 of 248

Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Heart Matters
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Improving Lipid Management Through Equity-Focused Clinical Strategies
Improving Lipid Management Through Equity-Focused Clinical Strategies
Heart Matters
Improving Lipid Management Through Equity-Focused Clinical Strategies
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Heart Matters
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Heart Matters
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
Cardiology
Efficacy of Obicetrapib Across Diverse Background Lipid-Lowering Regimens: Pooled BROADWAY & BROOKLYN Analyses
- Kausik Ray, MBChB, MD, MPhil
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Cardiology
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
- Kausik Ray, MBChB, MD, MPhil
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
Cardiology
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Cardiology
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Cardiology
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
- Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart Matters
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
- Kevin Alexander, MD
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart Matters
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart Matters
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart Matters
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Heart Matters
Analyzing Outpatient Worsening Heart Failure in ATTR-CM

4/9

Episodes 49-64 of 248

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy